Paolo Ghia received his MD from the University of Torino, Italy, and received his PhD working at the Basel Institute for Immunology, Switzerland, studying B lymphocyte development. He then studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly of follicular lymphoma at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.
He is now working in Milano, as Professor of Medical Oncology at the Università Vita-Salute San Raffaele; and Director of the Strategic Research Program on CLL, a clinical center at the affiliated Ospedale San Raffaele, dedicated to clinical research including a dedicated unit for phase 1 studies.
He is currently visiting the Lymphoma Division at the Dana-Farber Cancer Institute/Harvard Medical School in Boston, MA.
His research interest is the study of the molecular and cellular mechanisms acting in the natural history of Chronic Lymphocytic Leukemia (CLL), including Monoclonal B-cell Lymphocytosis (MBL). On these topics he has published over 400 manuscripts in peer-reviewed journals.
He is President of the European Research Initiative on CLL (ERIC), deputy Chair of the International Workshop on CLL (iwCLL) and member of the WHO Clinical Advisory Committee for Lymphocytic and Histiocytic Malignancies. He is co-leading author of the EHA guidelines for CLL treatment. He contributes to the ERIC recommendations on IGHV, TP53 and MRD analyses.